Cell & Gene: The Podcast - Erin Harris

Podcast details

Technical and general information from the podcast's RSS feed.

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX
119 shares

https://www.linkedin.com/in/erinharris/
119 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

Publication history

Monthly episode publishing history over the past years.

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

Episode 85

Thursday, September 12, 2024 • Duration 28:06

We love to hear from our listeners. Send us a message.

Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

Episode 84

Thursday, August 29, 2024 • Duration 25:13

We love to hear from our listeners. Send us a message.

Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is managed, it is not one that is often cured. In this episode, Host Erin Harris follows up Roberts' article with in-depth questions around existing issues with current CAR T approaches, "auto versus allo," and why allogeneic is the path forward. They also discuss how and why allogeneic therapies are truly scalable.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant

Episode 75

Thursday, May 9, 2024 • Duration 18:51

We love to hear from our listeners. Send us a message.

Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed the Kaposi’s Sarcoma Research & Education Foundation in 1982, which later became the San Francisco AIDS Foundation. On this episode, Dr. Conant shares they why behind cell and gene therapy to treat HIV, and he explains Addimmune’s lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah

Episode 74

Thursday, April 25, 2024 • Duration 29:39

We love to hear from our listeners. Send us a message.

BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.

Listen and subscribe so you never miss an episode!

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang

Episode 73

Thursday, April 11, 2024 • Duration 23:08

We love to hear from our listeners. Send us a message.

In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants. They also talk through Vor’s decision to build an internal cell therapy manufacturing facility co-located with their Cambridge, MA-based headquarters.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan

Episode 72

Thursday, March 28, 2024 • Duration 19:37

We love to hear from our listeners. Send us a message.

Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.

Episode 71

Thursday, March 14, 2024 • Duration 17:17

We love to hear from our listeners. Send us a message.

On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-based biotech's cellular rejuvenation therapies for the treatment of age-related diseases. They cover Life Biosciences' lead program, a gene therapy called OSK that is being advanced in two optic neuropathies – a rare eye disease of aging called non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. They also cover they why behind gene therapy as a modality, as well as Life Biosciences' partnership with Forge Biologics to manufacture AAV for the cellular rejuvenation technology.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz

Episode 70

Thursday, February 29, 2024 • Duration 27:31

We love to hear from our listeners. Send us a message.

Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz. They discuss RDTC's mission, the specific qualifications that make up a rare disease, how the study of rare diseases can potentially advance progress in common diseases, and much more.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald

Episode 69

Thursday, February 15, 2024 • Duration 20:48

We love to hear from our listeners. Send us a message.

On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta. They talk through the most significant steps Kite took to reach this approval, lessons learned from having worked with the FDA, scaling up technologies for cell therapy manufacturing, and more.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.

Episode 68

Thursday, February 1, 2024 • Duration 37:17

We love to hear from our listeners. Send us a message.

The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value for CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time to treatment issues typically experienced at launch. They cover obtaining adequate investment dollars, and much more.

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Read moreCollapse

Cell & Gene: The Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Cell & Gene: The Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other4

Youtube1

LinkedIn1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other4

Youtube1

LinkedIn1

Apple Podcasts

Spotify